Dasatinib (BMS-354835) Versus Imatinib Mesylate in Subjects With Chronic Myeloid Leukemia
Status:
Completed
Trial end date:
2008-03-01
Target enrollment:
Participant gender:
Summary
The primary purpose of this study is to estimate the major cytogenetic response rates of
BMS-354825 and imatinib (800 mg/d) in subjects with chronic phase, Philadelphia chromosome
positive, chronic myeloid leukemia (PH+ CML) with disease resistant to imatinib at a dose of
400-600 mg/d.